Primary resistant disease is clinically heterogeneous in metastatic renal cell carcinoma treated with nivolumab plus ipilimumab. (PubMed, Anticancer Drugs) - Oct 7, 2026 - "Elevated baseline CRP and lymph node involvement were associated with PRD-EM in an exploratory analysis. The PRD-EM classification and these associations require validation in larger independent cohorts before they can be used for clinical decision-making."
Heterogeneity • Journal • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • CRP
|
|
Kazuyuki Numakura; Masanao Shinohara; Naoki Fujita; Noriyuki Abe; Ryuma Tanaka; Satoshi Sato; Shin Kobayashi; Shingo Hatakeyama; Tomonori Habuchi; Yuya Sekine
|